Vivesto AB (LON:0N4A)

Market Cap	7.13M -28.0%
Revenue (ttm)	n/a
Net Income	-2.75M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,704,520
Average Volume	28,807
Open	0.0834
Previous Close	0.0826
Day's Range	0.0834 - 0.0834
52-Week Range	0.0826 - 0.2360
Beta	0.05
RSI	27.16
Earnings Date	Mar 2, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known a...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 4
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0N4A

Financial Performance

Financial numbers in SEK